Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II/III Study to Evaluate the Efficacy and Safety of BAT4406F Injection in Patients With Neuromyelitis Optica Lineage Disease

NCT06044350 is registered in ClinicalTrials.gov with Bio-Thera Solutions as lead sponsor.

NCT NCT06044350
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06044350 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II/III Study to Evaluate the Efficacy and Safety of BAT4406F Injection in Patients With Neuromyelitis Optica Lineage Disease
Lead sponsor
Bio-Thera Solutions
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 1, 2023
Completion date
December 31, 2027
Enrollment
162 (estimated)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

optic neuromyelitis spectrum disease